Executive Summary

The global medical technology industry is being reshaped by five structural forces that operate simultaneously and reinforce one another: Mainland China's expanding volume-based procurement (VBP) regime; the migration of procedures into outpatient and ambulatory surgical centre (ASC) settings; trade tensions and supply chain volatility; the rapid adoption of GLP-1 therapies; and the shift toward platform-based competition built on robotics, imaging, navigation and digital workflow software. Industry research published by Clarivate in April 2026 identifies these dynamics as the defining features of the 2026 medtech landscape.

The strategic significance lies in their interaction. Pricing pressure in one market alters portfolio priorities globally. Site-of-service migration changes product design and commercial coverage models. Supply chain reconfiguration raises capital intensity. Therapeutic substitution reallocates procedure volumes across therapy areas. And platform competition determines which companies capture the data, workflow and service revenue that surrounds the device itself.

For multinational manufacturers, the practical agenda is to treat these forces as a single integrated strategy problem spanning pricing, portfolio, manufacturing footprint and technology architecture, rather than as five separate regional or functional issues.

Introduction

Medical technology has long grown through a predictable sequence: generate clinical evidence, secure regulatory clearance, obtain reimbursement, then scale manufacturing and distribution. That sequence still governs individual products. It no longer explains industry-level outcomes.

In 2026, the determinants of growth and margin are increasingly structural. They include the reimbursement architecture that decides where a procedure is performed, the procurement rules that determine what a device is paid, the trade environment that determines where it is built, and the therapeutic landscape that determines whether the procedure happens at all. Products remain essential, but they compete inside systems that are themselves in motion.

This analysis draws on industry research published by Clarivate's Life Sciences & Healthcare practice, which identified five medtech trends to watch in 2026 through proprietary market data and expert assessment. It examines what each trend represents, why it matters commercially, and what it implies for corporate strategy over the coming three to ten years.

Business Context

The medtech sector sits at the intersection of three slow-moving systems — health financing, industrial policy and global trade — and one fast-moving system: clinical and digital innovation. The tension between them explains much of the current uncertainty.

Health financing systems in most advanced economies continue to prioritise cost containment. Large public procurement markets have expanded their use of price-setting mechanisms, while payers in the United States have steadily shifted lower-acuity procedures, and increasingly some higher-acuity procedures, toward outpatient and ambulatory settings where the total cost of care is lower.

Industrial policy has moved in the opposite direction, toward resilience. Tariff exposure, geopolitical friction and fluctuating input costs have turned concentrated, single-region manufacturing footprints into a strategic liability rather than a pure efficiency gain. At the same time, therapeutic innovation — most visibly in obesity and metabolic disease — is changing patient flows through the health system and, with them, the demand profile for devices used in adjacent specialties.

Meanwhile, the technology layer around devices has thickened. Robotics, intraoperative imaging, navigation and digital workflow software are converging into integrated systems that shape how procedures are planned, executed and followed up. The result is a sector in which competitive position depends as much on systems integration, supply chain design and reimbursement strategy as on device performance alone.

Main Analysis

1. Volume-based procurement in Mainland China is reshaping global pricing expectations

Mainland China's national volume-based procurement programme was originally conceived to expand patient access and reduce device costs. It has since evolved into a market-structuring mechanism. The newest procurement round introduces more sophisticated anchor-price logic, deeper price compression and allocation systems that support domestic manufacturers.

For multinational companies, the consequence extends beyond China. VBP is now influencing expectations around price, volume and competitive positioning in markets well beyond Mainland China, because global pricing architectures and tender benchmarks are interconnected. Participation in one of the world's largest device markets increasingly requires accepting a price trajectory that affects portfolio decisions elsewhere, while accelerating domestic innovation as local manufacturers scale under favourable allocation.

2. Site-of-service migration is becoming central to procedure strategy

The migration of procedures from hospitals to outpatient settings remains one of the most consequential structural trends in medtech. In the United States, the Centers for Medicare & Medicaid Services' 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule reinforces this direction by expanding the ASC Covered Procedure List and phasing out the inpatient-only list.

The practical effect is to open the door for higher-acuity procedures — cardiac ablation is a frequently cited example — to move into lower-cost settings when clinically appropriate. This builds on long-established patterns in orthopaedics and general surgery, where ASCs have already become central to growth strategies for both providers and manufacturers. As the eligible procedure set widens, device makers must adapt commercial coverage models, economic value propositions and product design to a more fragmented and cost-sensitive customer base.

3. Trade and supply chain pressure is rewriting manufacturing strategy

Supply chain resilience has moved from operational concern to strategic imperative. Tariff exposure, geopolitical factors and fluctuating material costs are challenging long-standing assumptions about where and how devices should be produced. Companies are responding by diversifying sourcing, re-evaluating business strategies and building more flexible multi-region manufacturing footprints.

Larger manufacturers are also using scale, integration and technology investment to buffer against volatility — a response that could further reshape competitive dynamics across categories. The implication is that cost structures, supplier concentration, manufacturing geography and portfolio rebalancing will increasingly determine competitive advantage, not just product performance.

4. GLP-1 therapies are altering patient behaviour and clinical pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is changing how patients and clinicians approach weight management and related comorbidities. Bariatric surgery remains the most effective intervention for substantial weight loss, but GLP-1 therapies have expanded quickly in popularity, shifting referral patterns and influencing demand across adjacent medtech categories.

The impact is not uniform. Certain bariatric procedures are experiencing sharper volume pressure than others, and downstream effects across diabetes care, sleep apnoea and cardiovascular monitoring are only beginning to emerge. The GLP-1 effect is therefore best understood not as a single product substitution but as a broader reconfiguration of how metabolic disease is managed, with ripple effects across multiple device markets and clinical pathways.

5. Enabling technologies are shifting competition toward platforms

Robotics, imaging, navigation and digital workflow software are reshaping how medtech companies differentiate. These technologies are no longer adjuncts to procedures; they are becoming the core of integrated ecosystems that support clinical planning, surgical execution and postoperative care.

Manufacturers are investing heavily in platform architectures capable of anchoring entire service lines, deepening customer relationships and unlocking data-driven value propositions. Emerging open-platform systems are expanding flexibility and creating new competitive dynamics, including competition over interoperability and the terms on which third parties can build. Platform-based competition is redefining how value is delivered, how customers are engaged and where long-term strategic advantage accumulates.

Commercial Impact

For manufacturers. The five trends compress revenue growth in some categories while opening it in others. Price compression in large procurement markets reduces the margin available to fund broad portfolios, pushing companies toward narrower, higher-value franchises and toward service, software and consumable revenue streams that are less exposed to unit-price deflation.

For providers and health systems. Site-of-service migration changes capital purchasing behaviour. Ambulatory operators require equipment that is compact, standardised, quick to turn over and supported by predictable service economics — a different specification set from that of large acute hospitals.

For global trade and supply chains. Multi-region manufacturing raises fixed costs but lowers concentration risk. Tariff exposure and material cost volatility make total landed cost modelling more complex, and they favour suppliers able to shift production between geographies without requalification delays.

For investors. Platform-based competition increases the strategic value of installed bases, data rights and workflow integration, while raising the capital intensity required to compete. Valuation frameworks that reward only near-term product revenue may understate the option value of ecosystem positions — and overstate the durability of categories exposed to therapeutic substitution.

For emerging manufacturers. Domestic allocation advantages in large procurement markets create a funding and scale pathway for local challengers, particularly in mid-acuity device categories. This increases competitive intensity in export markets over time.

For consumers and payers. Lower-cost sites of care and price-based procurement can expand access, but they also raise questions about clinical appropriateness criteria, quality monitoring and the sustainability of supplier margins in lower-volume specialties.

Strategic Insights

Pricing strategy must be global, not local. Procurement outcomes in a single large market increasingly propagate through global reference pricing and tender benchmarking. Companies that treat VBP as a China-specific issue tend to discover its effects later in other tenders.

Site-of-service is now a product strategy question. Design decisions — device footprint, sterility and reprocessing requirements, training burden, service model — determine whether a product is viable in ambulatory settings. Commercial coverage models built around hospital call points may need restructuring.

Supply chain design is a competitive variable. Flexibility across regions, dual sourcing of critical components and visibility into tier-two suppliers are becoming differentiators rather than insurance policies. Larger manufacturers can convert scale into resilience; smaller ones may need partnership or contract manufacturing arrangements to achieve comparable optionality.

Therapeutic substitution demands portfolio stress-testing. The GLP-1 effect illustrates how a pharmaceutical innovation can reallocate demand across surgical and monitoring device categories. Scenario planning across procedure volumes is becoming a standard element of portfolio review.

Platform positions are defensible; feature advantages are not. Robotics, imaging, navigation and workflow software reinforce one another. Companies that integrate them capture switching costs and data advantages, while those offering standalone hardware compete on price and specification alone.

Regulatory and policy engagement is a commercial function. Reimbursement rules, procurement design, tariff policy and digital governance all shape addressable markets. Corporate strategy teams increasingly need the same quality of policy intelligence as regulatory affairs.

Future Outlook

Over the next three to ten years, several trajectories appear plausible, though their pace will depend on policy decisions, clinical evidence and capital availability.

Artificial intelligence becomes infrastructure. AI is likely to move from discrete features to embedded infrastructure across imaging interpretation, surgical planning, workflow triage and postoperative monitoring. The competitive question shifts from whether a device has AI to who controls the data pipeline and validation evidence behind it.

Procurement mechanisms spread and mature. Price-setting programmes in large markets are likely to extend to additional device categories and to incorporate quality and outcomes criteria alongside price. Domestic industrial development objectives will remain a visible component of design.

Care continues to decentralise. Site-of-service migration is likely to broaden beyond orthopaedics and general surgery into cardiology, interventional radiology and selected oncology procedures, subject to clinical evidence and payer policy. This reshapes the customer base for capital equipment and the economics of service networks.

Supply chains become regionally diversified but not fully decoupled. Most manufacturers are likely to operate multi-region footprints with redundant capacity in critical components, accepting higher fixed costs in exchange for lower disruption risk.

Metabolic disease management stabilises into a hybrid model. GLP-1 therapies and surgical interventions are likely to coexist, with device demand concentrating in monitoring, complications management and specific procedure types rather than disappearing uniformly.

Platform consolidation and interoperability pressure increase. Expect continued investment in integrated ecosystems, alongside regulatory and purchaser pressure for open interfaces and data portability — a tension that will shape partnership strategies.

Workforce and skills shift. Demand grows for engineers and commercial staff fluent in software, data and health economics, alongside traditional clinical and regulatory expertise.

Conclusion

The 2026 medtech landscape is less defined by individual product breakthroughs than by the interaction of pricing systems, care delivery models, trade conditions, therapeutic innovation and technology platforms. Each force is significant on its own; together they determine which companies can sustain margins, where growth migrates, and how competitive advantage is built.

For executives, the practical implication is that strategy reviews can no longer treat market access, manufacturing footprint, portfolio composition and technology architecture as separate workstreams. They are now different views of the same problem. Companies that integrate them early are likely to find that the shifting structure of global medtech is an opportunity to reposition, while those that respond issue by issue may find the window narrowing.

Key Takeaways

• Five forces are converging on medtech in 2026: volume-based procurement in Mainland China, site-of-service migration, trade and supply chain volatility, GLP-1 adoption, and platform-based competition.
• VBP has evolved from an access and cost-control programme into a market-structuring mechanism, with effects on global pricing expectations beyond Mainland China.
• The CMS 2026 OPPS and ASC final rule expands the ASC Covered Procedure List and phases out the inpatient-only list, supporting movement of higher-acuity procedures into lower-cost settings.
• Tariff exposure and material cost volatility are driving diversified sourcing and multi-region manufacturing, raising capital intensity while reducing concentration risk.
• GLP-1 therapies are changing referral patterns and procedure volumes unevenly, with downstream effects emerging in diabetes, sleep apnoea and cardiovascular monitoring.
• Robotics, imaging, navigation and digital workflow software are turning competition into a contest over integrated platforms, data rights and installed-base economics.
• The strategic response requires integration across pricing, portfolio, supply chain and technology decisions rather than isolated functional initiatives.

SEO Keywords

Global Commerce; International Business; Corporate Strategy; Digital Transformation; Artificial Intelligence; International Trade; Supply Chain; Business Innovation; Global Economy; Investment; Manufacturing; Retail and Consumer Markets; Digital Economy; Business Leadership; Economic Development; Corporate Finance; Entrepreneurship; Market Trends; Business Technology; Commercial Strategy

Sources

• Clarivate, Life Sciences & Healthcare — 5 medtech trends to watch in 2026 (April 28, 2026): https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026
• Clarivate, Medtech Trends to Watch 2026 report landing page: https://clarivate.com/life-sciences-healthcare/lp/medtech-trends-to-watch-in-2026/
• U.S. Centers for Medicare & Medicaid Services, Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule: https://www.cms.gov